Sanofi India Limited (SANOFI) fundamentals
Sanofi India Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as SANOFI (ISIN INE058A01010). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Sanofi India Limited does
Sanofi India Limited is an India-based company, which is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. The Company produces pharmaceutical formulations, dosage forms and offer a range of medicines across various therapeutic areas. Its product portfolio is focused on five therapeutic areas: diabetes, epilepsy, cardiology, allergy and pain care. In the diabetes area, the Company has an insulin portfolio under the brand name of Lantus, which helps in controlling high blood sugar in adults and children with diabetes mellitus. It also provides Toustar pen, along with dedicated Toujeo cartridges, addressing the need for a reusable delivery device. Combiflam, its product, helps to reduce pain and inflammation in conditions like headache, muscle and joint pain, and also reduces fever. Its brands also include Cardace, Allegra, Avil and Frisium. The Company has its own manufacturing facility in Goa. It has around 12 contract manufacturing organizations.
Valuation and market data
| Last close | ₹3082.90 |
|---|---|
| Market capitalisation | ₹7,100 crore |
| Enterprise value | ₹6,852 crore |
| P/E (TTM) | 21.73 |
| Price to book | 9.48 |
| Price to sales (TTM) | 2.19 |
| Book value per share | ₹325.30 |
| Dividend yield | 398.97% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Mon May 19 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Dec 2025 | ₹1,857 crore | ₹445 crore | ₹327 crore | 141.85 |
| Dec 2024 | ₹2,030 crore | ₹431 crore | ₹314 crore | 179.54 |
| Dec 2023 | ₹2,916 crore | ₹846 crore | ₹603 crore | 261.91 |
| Dec 2022 | ₹2,842 crore | ₹864 crore | ₹621 crore | 269.47 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 60.4% |
|---|---|
| Foreign institutions (FII) | 5.7% |
| Mutual funds | 9.1% |
| Other domestic institutions | 10.7% |
| Retail and others | 14.0% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.